Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545142 | 0.81 | MAOA (0.54) | LTA4HMAOACA2CA9MEN1 | |
| SCHEMBL3827661 | 0.80 | LTA4H (0.63) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL435149 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL11576945 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL22129853 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL9212518 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL122719 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL3893562 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL6681158 | 0.78 | LTA4H (0.60) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL28067265 | 0.76 | TDP1 (0.53) | TSHRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379533-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | Leo Pharma A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| CN-1443190-A | Matrix metalloproteinase inhibitors | LEO PHARM PROD LTD (DK) | 2003-09-17 | — | — | CN | disclosed |
| US-6605742-B2 | Rheumatic diseases; antiarthritic agents; antitumor agents | LEO PHARMA A/S (DK) | 2003-08-12 | — | — | US | disclosed |
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083696-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | CMA1, MMP9, CPA1 | LTA4H 31/4885TSHR 4193/4885NR1H2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.